Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma (Q73181807)
Jump to navigation
Jump to search
scientific article published on 01 September 1999
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma |
scientific article published on 01 September 1999 |
Statements
Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma (English)
S J O'Day
G Gammon
P D Boasberg
M A Martin
T S Kristedja
M Guo
S Stern
S Edwards
P Fournier
M Weisberg
M Cannon
N W Fawzy
T D Johnson
R Essner
L J Foshag
1 September 1999